Eli Lilly Was Such a Healthy Stock
Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years
We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other the Stock That Will Make You Rich in 5-10 Years.
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Eli Lilly, Insitro ink a new kind of AI drug development deal
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Eli Lilly and Company invests additional $4.5 billion to LEAP
Eli Lilly and Company announced an increased budget for the LEAP by $4.5 billion. The increased budget goes toward the Lilly Medicine Foundry in the proposed LEAP district.
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
CIO Dive4h
Eli Lilly names first chief AI officer
Thomas Fuchs will lead AI initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.
FiercePharma1d
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
Becker's Hospital Review11h
Eli Lilly snags chief AI officer from Mount Sinai
Discover how Eli Lilly & Co. is focused on healthcare innovation by naming Thomas Fuchs, formerly of Mount Sinai Health System, its first chief AI officer.
Yahoo Finance6d
Here’s Why Eli Lilly and Company (LLY) Surged in Q2
PGIM Jennison Health Sciences Fund highlighted stocks like Eli Lilly and Company (NYSE:LLY) in the second quarter 2024 investor letter. Eli Lilly and Company (NYSE:LLY) is a pharmaceutical ...
FierceBiotech2d
AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...